KESTRA MEDICAL TECHNOLOGIES, LTD.
For the period ended Apr 30, 2025. Filed Jul 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Jul 17, 2025
KMTS$30.12+4.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| April 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $237,595 | $8,249 |
| Accounts receivable, net | 8,081 | 1,998 |
| Disposable medical equipment supplies | 6,572 | 3,290 |
| Prepaid expenses and other current assets | 3,080 | 1,370 |
| Total current assets | 255,328 | 14,907 |
| Right-of-use assets | 2,078 | 2,286 |
| Deposits | 2,021 | 1,710 |
| Restricted cash | 334 | 334 |
| Property and equipment, net | 34,830 | 26,105 |
| Other long-term assets | 1,153 | 607 |
| Total assets | $295,744 | $45,949 |
| Liabilities, Redeemable Preferred Stock and Shareholders’ Equity (Deficit) | ||
| Current liabilities | ||
| Accounts payable | $23,961 | $23,892 |
| Accrued liabilities | 13,829 | 9,079 |
| Operating lease liabilities, current portion | 187 | — |
| Total current liabilities | 37,977 | 32,971 |
| Operating lease liabilities, net of current portion | 3,026 | 2,633 |
| Warrant liabilities | 8,097 | — |
| Other long-term liabilities | 140 | 76 |
| Long-term debt, net | 41,098 | 42,536 |
| Total liabilities | 90,338 | 78,216 |
| Commitments and contingencies (Note 14) | ||
| Redeemable preferred stock, $0.01 par value; 0 and 5,000,000 shares authorized as of April 30, 2025 and April 30, 2024, respectively; 0 and 177,110 shares issued and outstanding as of April 30, 2025 and April 30, 2024, respectively | — | 177,110 |
| Shareholders’ equity (deficit) | ||
| Common stock, $0.01 par value; 5,000,000 shares authorized as of April 30, 2024; 105,808 shares issued and outstanding as of April 30, 2024 | — | 19,909 |
| Common shares, $1.00 par value; 100,000,000 shares authorized as of April 30, 2025; 51,348,656 shares issued and outstanding as of April 30, 2025 | 51,349 | — |
| Additional paid-in capital | 674,306 | 177,149 |
| Accumulated deficit | (520,249) | (406,435) |
| Total shareholders’ equity (deficit) | 205,406 | (209,377) |
| Total liabilities and shareholders’ equity (deficit) | $295,744 | $45,949 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.